Laser ablation inductively coupled plasma mass spectrometry imaging of metals in experimental and clinical Wilson's disease

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 4, 2015, Pages 806-814

  Boaru, Sorina Georgiana ^a   Merle, Uta ^b   Uerlings, Ricarda ^a   Zimmermann, Astrid ^c   Flechtenmacher, Christa ^b   Willheim, Claudia ^d   Eder, Elisabeth ^d   Ferenci, Peter ^d   Stremmel, Wolfgang ^b   Weiskirchen, Ralf ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c JÜLICH RESEARCH CENTRE   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Laser ablation inductively coupled plasma mass spectrometry; Liver; Metal bio imaging; Trace metals; Wilson's disease

Indexed keywords

MURINAE; MUS;

ADENOSINE TRIPHOSPHATASE; CATION TRANSPORT PROTEIN; COPPER; INTERLEUKIN 1BETA; IRON; METAL; TISSUE INHIBITOR OF METALLOPROTEINASE 1; WILSON DISEASE PROTEIN; ZINC;

129 MOUSE; ADOLESCENT; ANIMAL; DIAGNOSTIC IMAGING; DISEASE MODEL; DNA MUTATIONAL ANALYSIS; FEMALE; GENETICS; HEPATOLENTICULAR DEGENERATION; HUMAN; KNOCKOUT MOUSE; LIVER; LOW LEVEL LASER THERAPY; MALE; MASS SPECTROMETRY; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; YOUNG ADULT;

ADENOSINE TRIPHOSPHATASES; ADOLESCENT; ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CATION TRANSPORT PROTEINS; COPPER; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; DNA MUTATIONAL ANALYSIS; FEMALE; HEPATOLENTICULAR DEGENERATION; HUMANS; INTERLEUKIN-1BETA; IRON; LASER THERAPY; LIVER; MALE; MASS SPECTROMETRY; METALS; MICE, 129 STRAIN; MICE, KNOCKOUT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; YOUNG ADULT; ZINC;

EID: 84925945301     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12497     Document Type: Article

References (45)

1. Ala A, Walker AP, Ashkan K, et al. Wilson's disease. Lancet. 2007; 369: 397-408.
2. de Bie P, Muller P, Wijmenga C, et al. Molecular pathogenesis of Wilson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes. J Med Genet. 2007; 44: 673-88.
3. Frydman M, Bonne-Tamir B, Farrer LA, et al. Assignment of the gene for Wilson disease to chromosome 13: linkage to the esterase D locus. Proc Natl Acad Sci USA. 1985; 82: 1819-21.
4. Bull PC, Thomas GR, Rommens JM, et al. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet. 1993; 5: 327-37.
5. Tanzi RE, Petrukhin K, Chernov I, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet. 1993; 5: 344-50.
6. Kitzberger R, Madl C, Ferenci P. Wilson disease. Metab Brain Dis. 2005; 20: 295-302.
7. Merle U, Schaefer M, Ferenci P, et al. Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study. Gut. 2007; 56: 115-20.
8. Roberts EA, Schilsky ML. A practice guideline on Wilson disease. Hepatology. 2003; 37: 1475-92.
9. Roberts EA, Schilsky ML. American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008; 47: 2089-111.
10. Ferenci P, Czlonkowska A, Stremmel W, et al. European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol. 2012; 56: 671-85.
11. Bennett J, Hahn SH. Clinical molecular diagnosis of Wilson disease. Semin Liver Dis. 2011; 31: 233-8.
12. Brewer GJ, Hill GM, Prasad AS, et al. Oral zinc therapy for Wilson's disease. Ann Intern Med. 1983; 99: 314-9.
13. Hill GM, Brewer GJ, Prasad AS, et al. Treatment of Wilson's disease with zinc. I. Oral zinc therapy regimens. Hepatology. 1987; 7: 522-8.
14. M-M P, Weiskirchen R, Gassler N, et al. Novel bioimaging techniques of metals by laser ablation inductively coupled plasma mass spectrometry for diagnosis of fibrotic and cirrhotic liver disorders. PLoS ONE. 2013; 8: e58702.
15. M-M P, Merle U, Weiskirchen R, et al. Bioimaging of copper deposition in Wilson's diseases mouse liver by laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MSI). Int J Mass Spectrom. 2013; 354-355: 281-7.
16. Buiakova OI, Xu J, Lutsenko S, et al. Null mutation of the murine ATP7B (Wilson disease) gene results in intracellular copper accumulation and late-onset hepatic nodular transformation. Hum Mol Genet. 1999; 8: 1665-71.
17. Sauer SW, Merle U, Opp S, et al. Severe dysfunction of respiratory chain and cholesterol metabolism in Atp7b(-/-) mice as a model for Wilson disease. Biochim Biophys Acta. 2011; 1812: 1607-15.
18. Peng F, Lutsenko S, Sun X, et al. Positron emission tomography of copper metabolism in the Atp7b-/- knock-out mouse model of Wilson's disease. Mol Imaging Biol. 2012; 14: 70-8.
19. Ferenci P. Wilson's Disease. Clin Gastroenterol Hepatol. 2005; 3: 726-33.
20. Boaru SG, Borkham-Kamphorst E, Tihaa L, et al. Expression analysis of inflammasomes in experimental models of inflammatory and fibrotic liver disease. J Inflamm. 2012; 9: 49.
21. Borkham-Kamphorst E, van de Leur E, Zimmermann HW, et al. Protective effects of lipocalin-2 (LCN2) in acute liver injury suggest a novel function in liver homeostasis. Biochim Biophys Acta. 2013; 1832: 660-73.
22. Osterholt T, Salber D, Matusch A, et al. IMAGENA: Image Generation and Analysis - An interactive software tool handling LA-ICP-MS data. Int J Mass Spectrom. 2011; 307: 232-9.
23. Becker JS, Kumtabtim U, Wu B, et al. Mass spectrometry imaging (MSI) of metals in mouse spinal cord by laser ablation ICP-MS. Metallomics. 2012; 4: 284-8.
24. Ferenci P, Steindl-Munda P, Vogel W, et al. Diagnostic value of quantitative hepatic copper determination in patients with Wilson's Disease. Clin Gastroenterol Hepato. 2005; 3: 811-8.
25. Martins da Costa C, Baldwin D, Portmann B, et al. Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease. Hepatology. 1992; 15: 609-15.
26. Hoogenraad TU, Koevoet R, de Ruyter Korver EG. Oral zinc sulphate as long-term treatment in Wilson's disease (hepatolenticular degeneration). Eur Neurol. 1979; 18: 205-11.
27. Schilsky ML, Blank RR, Czaja MJ, et al. Hepatocellular copper toxicity and its attenuation by zinc. J Clin Invest. 1989; 84: 1562-8.
28. Mulder TP, Janssens AR, Verspaget HW, et al. Metallothionein concentration in the liver of patients with Wilson's disease, primary biliary cirrhosis, and liver metastasis of colorectal cancer. J Hepatol. 1992; 16: 346-50.
29. Konz I, Fernández B, Fernández ML, et al. Laser ablation ICP-MS for quantitative biomedical applications. Anal Bioanal Chem. 2012; 403: 2113-25.
30. Arnal N, de Alaniz MJ, Marra CA. Effect of copper overload on the survival of HepG2 and A-549 human-derived cells. Hum Exp Toxicol. 2013; 32: 299-315.
31. Payne AS, Kelly EJ, Gitlin JD. Functional expression of the Wilson disease protein reveals mislocalization and impaired copper-dependent trafficking of the common H1069Q mutation. Proc Natl Acad Sci USA. 1998; 95: 10854-9.
32. van den Berghe PV, Stapelbroek JM, Krieger E, et al. Reduced expression of ATP7B affected by Wilson disease-causing mutations is rescued by pharmacological folding chaperones 4-phenylbutyrate and curcumin. Hepatology. 2009; 50: 1783-95.
33. Kumar S, Thapa B, Kaur G, et al. Analysis of most common mutations R778G, R778L, R778W, I1102T and H1069Q in Indian Wilson disease patients: correlation between genotype/phenotype/copper ATPase activity. Mol Cell Biochem. 2007; 294: 1-10.
34. Huster D, Kühne A, Bhattacharjee A, et al. Diverse functional properties of Wilson disease ATP7B variants. Gastroenterology. 2012; 142: 947-56.e5.
35. Allen KJ, Buck NE, Cheah DM, et al. Chronological changes in tissue copper, zinc and iron in the toxic milk mouse and effects of copper loading. Biometals. 2006; 19: 555-64.
36. Shiono Y, Wakusawa S, Hayashi H, et al. Iron accumulation in the liver of male patients with Wilson's disease. Am J Gastroenterol. 2001; 96: 3147-51.
37. Phillips MJ, Ackerley CA, Superina RA, et al. Excess zinc associated with severe progressive cholestasis in Cree and Ojibwa-Cree children. Lancet. 1996; 347: 866-8.
38. Chabanova E, Logager V, Moller JM, et al. Imaging liver metastases with a new oral manganese-based contrast agent. Acad Radiol. 2006; 13: 827-32.
39. Rief M, Huppertz A, Asbach P, et al. Manganese-based oral contrast agent for liver magnetic resonance imaging: evaluation of the time course and dose response of liver signal intensity enhancement. Invest Radiol. 2010; 45: 565-71.
40. Ballatori N. Molecular mechanisms of hepatic metal transport. In: Zalups RK, Koropatnick J, editors. Molecular biology and toxicology of metals. New York: Taylor & Francis; 2000. pp. 346-81.
41. Hauser RA, Zesiewicz TA, Rosemurgy AS, et al. Manganese intoxication and chronic liver failure. Ann Neurol. 1994; 36: 871-5.
42. Jüngst C, Cheng B, Gehrke R, et al. Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma. Hepatology. 2004; 39: 1663-72.
43. Hayashi H, Hattori A, Tatsumi Y, et al. Various copper and iron overload patterns in the livers of patients with Wilson disease and idiopathic copper toxicosis. Med Mol Morphol. 2013; 46: 133-40.
44. Herdering C, Wehe CA, Reifschneider O, et al. Laser ablation based bioimaging with simultaneous elemental and molecular mass spectrometry: towards spatially resolved speciation analysis. Rapid Commun Mass Spectrom. 2013; 27: 2588-94.
45. Wang HA, Grolimund D, Giesen C, et al. Fast chemical imaging at high spatial resolution by laser ablation inductively coupled plasma mass spectrometry. Anal Chem. 2013; 85: 10107-16.